NCT01928628

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 449 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to compare and assess the efficacy and the safety of the combination agent of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential hypertension

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Lercanidipine 10mg
DRUG	Lercanidipine10mg /Valsartan 80mg
DRUG	Lercanidipine 10mg /Valsartan 160mg
DRUG	Lercanidipin 10mg Placebo
DRUG	Lercanidipine10mg /Valsartan 80mg Placebo
DRUG	Lercanidipine 10mg /Valsartan 160mg Placebo

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-04-01
• First posted: 2013-08-27
• Last updated: 2013-08-28

Locations

1 site across 1 country: South Korea